Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2016

01.02.2016

Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience

verfasst von: Kelsey Klute, Ersilia M. DeFilippis, Kelissa Shillingford, John Chapin, Maria T. DeSancho

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Splanchnic vein thrombosis (SVT) is an uncommon form of venous thrombosis. Management can be challenging due to underlying conditions, increased bleeding risk, and lack of evidence from clinical trials. We sought to characterize the presentation and management of patients with SVT at a large tertiary hospital. A total of 43 patients’ electronic medical records were reviewed. Median age at diagnosis was 43 (18–71). Sixteen patients had isolated portal vein thrombosis (37.2 %), and 16 (37.2 %) had thrombosis involving multiple splanchnic veins. Abdominal pain was the most common clinical presentation (67.4 %). Thrombophilia was present in 18 patients (41.9 %), nine had underlying liver disease (20.9 %) and seven had inflammatory bowel disease (16.3 %). Thirty-nine (90.7 %) patients were treated with anticoagulation, and 11(25.6 %) of these patients underwent interventional procedures. Thirty (69.8 %) patients remained on indefinite anticoagulation. Results of follow-up imaging at least 1 month after diagnosis were available for 29 patients; imaging showed chronic, stable thrombosis in 14 patients (48.3 %), resolution of thrombosis in 13 patients (44.8 %) and asymptomatic progression in two patients (6.9 %). Recurrent thrombosis occurred in four patients (9.3 %). Major bleeding occurred in eight patients who received anticoagulation (18.6 %), including fatal subdural hematoma in one patient. In this cohort of patients managed by hematologists and gastroenterologists, the majority of patients were treated with anticoagulation. Interventional procedures were higher than in previously reported series. Our study strongly supports the interdisciplinary management of splanchnic venous thrombosis.
Literatur
1.
Zurück zum Zitat Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH (2006) Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 12:2115–2119CrossRefPubMedPubMedCentral Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH (2006) Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 12:2115–2119CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Ageno W, Riva N, Schulman S et al (2014) Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost 40:99–105PubMed Ageno W, Riva N, Schulman S et al (2014) Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost 40:99–105PubMed
3.
Zurück zum Zitat Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W (2012) Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 130(Suppl 1):S1–S3CrossRefPubMed Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W (2012) Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 130(Suppl 1):S1–S3CrossRefPubMed
4.
Zurück zum Zitat Amitrano L, Guardascione MA, Scaglione M et al (2012) Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. Eur J Gastroenterol Hepatol 24:1381–1385CrossRefPubMed Amitrano L, Guardascione MA, Scaglione M et al (2012) Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. Eur J Gastroenterol Hepatol 24:1381–1385CrossRefPubMed
5.
Zurück zum Zitat Yonal I, Pinarbasi B, Hindilerden F et al (2012) The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. J Thromb Thrombolysis 34:388–396CrossRefPubMed Yonal I, Pinarbasi B, Hindilerden F et al (2012) The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. J Thromb Thrombolysis 34:388–396CrossRefPubMed
6.
Zurück zum Zitat Sekhar M, McVinnie K, Burroughs AK (2013) Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 162:730–747CrossRefPubMed Sekhar M, McVinnie K, Burroughs AK (2013) Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 162:730–747CrossRefPubMed
7.
Zurück zum Zitat Hoekstra J, Leebeek FW, Plessier A et al (2009) Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 51:696–706CrossRefPubMed Hoekstra J, Leebeek FW, Plessier A et al (2009) Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 51:696–706CrossRefPubMed
8.
Zurück zum Zitat Mutreja D, Kotru M, Sazawal S et al (2015) Hereditary and acquired thrombophilia in splanchnic vein thrombosis: a single-center experience. Clin Appl Thromb Hemost 21:521–526CrossRefPubMed Mutreja D, Kotru M, Sazawal S et al (2015) Hereditary and acquired thrombophilia in splanchnic vein thrombosis: a single-center experience. Clin Appl Thromb Hemost 21:521–526CrossRefPubMed
9.
Zurück zum Zitat Bianchini M, De Pietri L, Villa E (2014) Coagulopathy in liver diseases: complication or therapy? Dig Dis 32:609–614CrossRefPubMed Bianchini M, De Pietri L, Villa E (2014) Coagulopathy in liver diseases: complication or therapy? Dig Dis 32:609–614CrossRefPubMed
10.
Zurück zum Zitat Tait C, Baglin T, Watson H et al (2012) Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 159:28–38CrossRefPubMed Tait C, Baglin T, Watson H et al (2012) Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 159:28–38CrossRefPubMed
11.
Zurück zum Zitat Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120:4921–4928CrossRefPubMed Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120:4921–4928CrossRefPubMed
12.
Zurück zum Zitat Colaizzo D, Amitrano L, Guardascione MA et al (2013) Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res 132:e99–e104CrossRefPubMed Colaizzo D, Amitrano L, Guardascione MA et al (2013) Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res 132:e99–e104CrossRefPubMed
13.
Zurück zum Zitat Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494SCrossRefPubMedPubMedCentral Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494SCrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694CrossRefPubMed Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694CrossRefPubMed
16.
Zurück zum Zitat Martinez M, Tandra A, Vuppalanchi R (2014) Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatol 60:425–426CrossRef Martinez M, Tandra A, Vuppalanchi R (2014) Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatol 60:425–426CrossRef
17.
Zurück zum Zitat Lenz K, Dieplinger B, Buder R, Piringer P, Rauch M, Voglmayr M (2014) Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban. Z Gastroenterol 52:1175–1177CrossRefPubMed Lenz K, Dieplinger B, Buder R, Piringer P, Rauch M, Voglmayr M (2014) Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban. Z Gastroenterol 52:1175–1177CrossRefPubMed
18.
Zurück zum Zitat Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424CrossRefPubMed Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424CrossRefPubMed
19.
Zurück zum Zitat Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for Dabigatran Reversal. N Engl J Med 373:511–520CrossRefPubMed Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for Dabigatran Reversal. N Engl J Med 373:511–520CrossRefPubMed
Metadaten
Titel
Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience
verfasst von
Kelsey Klute
Ersilia M. DeFilippis
Kelissa Shillingford
John Chapin
Maria T. DeSancho
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2016
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1337-4

Weitere Artikel der Ausgabe 2/2016

Journal of Thrombosis and Thrombolysis 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Nierenultraschall: Tipps vom Profi

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.